The Molecular Characterization of Genetic Abnormalities in Esophageal Squamous Cell Carcinoma May Foster the Development of Targeted Therapies
Jenny Que
Round 1
Reviewer 1 Report
In this review article submitted for publication in Current Oncology, Ugo et al. summarized the recent advancements on the molecular characterization of genetic abnormalities in esophageal squamous cell carcinoma for the development of targeted therapies. This is a comprehensive review of the extremely important topic of genetic abnormalities in esophageal squamous cell carcinoma. Figure 1 is especially informative and helpful for the researchers working in this area.
On page 6, paragraph 2; table 53 is mentioned. It seems a typo error, please correct this. The manuscript can be accepted in the current format after proof-reading to avoid the typo and few grammar mistakes.
Author Response
Reply to reviewer 1
The typo error present on page 6, paragraph 2, Table 53 was corrected.
Furthermore other typo errors present in the manuscript have been corrected
Reviewer 2 Report
Reviewer's report:
This is an interesting manuscript as it’s a comprehensive review analysing the recent developments in the characterization of the molecular defects of ESCCs, attempting to define their complexity, heterogeneity with the identification of some subgroups the could be amenable to molecular targeted treatments as well as immunotherapy. These studies have led to suggest that about 40% of these molecular abnormalities are actionable. However, the first studies of molecular targeting of some of these molecular abnormalities showed only a limited therapeutic benefit, which are consistent to the heterogeneity of ESCCs. While ICIs concurrent with chemotherapy may also improve the benefit for the treatment of ESCC patients with locally advanced disease However, the results of ongoing phase III studies are needed to assess their real therapeutic impact in this setting
The MS is well prepared and containing a large amount of data. Although, there remain some limitation such redundant report of various study . Nevertheless, it was still well written, however, a few issue need to be clarify prior publication..
1. several typo-error should be corrected prior publication.
e.g. Page 2, 2nd paragraph ..
1. …In some areas of Chine the risk of …
2. ….Feicheng in China: 3731 subjects subjects resulted …
3. ….time for progression to ESCC for patients with mild ESD waqs 3.5 years …
4. … between matched ESD and ESSC ? samples were considered as trunk events
5. …identification of driver genes underlying the development of ESSC ? from ESD;
Page 2, 3rd paragraph
observed with concomitant ESSC ? and 13 ESD samples...
Author Response
Reply to reviewer 2
All typo-errors indicated by the reviewer have been corrected.
Furthermore, other typo errors present in the manuscript have been corrected
